TANGO THERAPEUTICS INC (TNGX) Stock Income Statement
NASDAQ:TNGX - Nasdaq - US87583X1090 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 40.99M | 42.07M | 36.53M | 24.86M | 37.04M | |||
| Operating Expenses | 186.00M | 188.00M | 151.00M | 135.93M | 95.23M | |||
| Research and Development | 142.30M | 143.92M | 115.20M | 105.91M | 77.64M | |||
| Selling, General, and Administrative Expenses | 44.00M | 44.00M | 36.00M | 30.03M | 17.60M | |||
| Operating Income | -147.00M | -146.00M | -114.00M | -111.07M | -58.19M | |||
| Interest Income/Expense | 7.31M | 7.89M | 6.62M | 1.46M | 500.00K | |||
| Other Income/Expense | 6.51M | 7.61M | 5.94M | 1.49M | -250.00K | |||
| Income Before Taxes | -132.00M | -130.00M | -102.00M | -108.12M | -57.94M | |||
| Income Tax | 200.00K | 210.00K | 130.00K | 50.00K | 290.00K | |||
| Net Income | -133.00M | -130.00M | -102.00M | -108.18M | -58.24M | |||
| EBITDA | -144.51M | -143.50M | -111.58M | -109.46M | -57.29M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.21 | -1.19 | -1.08 | -1.23 | -0.94 | |||
| Non GAAP EPS | -1.22 | -1.21 | -1.10 | -1.23 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -324.46% | -309.02% | -279.25% | -435.16% | -157.24% | |||
| Operating Profit Margin | -358.62% | -347.05% | -312.10% | -446.78% | -157.10% | |||
All data in USD